Led · Series C · Dec 2020

EclecticIQ builds an analyst-centric, open and extendable cybersecurity platform that combines threat intelligence automation and collaboration with forensic endpoint visibility and threat detection and response. Founded in 2014 by Joep Gommers and Raymon van der Velde, the company helps governments, large enterprises, and service providers manage threat intelligence and create situational awareness. It extended into hunting and response after acquiring Polylogyx's endpoint technology in 2020. The company operates worldwide with teams and offices in Europe, the UK, North America and India and works through value-added partners. EclecticIQ plans to use recent financing to accelerate R&D, further develop its platform, and expand into new countries and sectors through sales and marketing investment. The articles position the firm as a scale-up addressing a rising global cyber threat landscape. EclecticIQ develops threat intelligence, hunting and response technology that helps large enterprises, service providers and governments manage threat intelligence and create situational awareness. The company extended its capabilities into hunting and response with the 2020 acquisition of Polylogyx’s endpoint technology. EclecticIQ intends to use new funding to expand its product portfolio with additional use cases and to promote an intelligence-led cybersecurity approach. Management plans to increase its global presence by extending commercial teams in Europe and the United States and establishing operations in the Middle East, Africa and Asia Pacific. The company also aims to strengthen its global partner ecosystem. Founded in 2014, EclecticIQ operates globally with offices across Europe, North America and via certified value-add partners. EclecticIQ offers an analyst-centric suite of cyber threat intelligence products, including the EclecticIQ Platform (based on STIX/TAXII) and the EclecticIQ Fusion Center for acquiring thematic intelligence bundles. The company targets security professionals in threat intelligence, threat hunting, SOC, and incident response roles. It employs a team of about 60 across offices in Amsterdam, London, and Herndon (Virginia, USA). EclecticIQ intends to use its latest funding to accelerate workforce expansion and to broaden its portfolio of technologies and Fusion Center capabilities. Financially, the company has raised more than €20m to date following its latest round. Founded in 2014 by Joep Gommers and Raymon van der Velde, EclecticIQ continues to expand its product and service offerings for enterprise security operations. EclecticIQ provides a Threat Intelligence Platform (TIP) that enables operationalization of security information exchange, empowers collaborative analyst workflow and integrates cyber threat intelligence for detection, prevention and response. Led by CEO and founder Joep Gommers, the company mainly serves financial institutions and government agencies. It is based in Amsterdam and also maintains offices in London and Chișinău, Moldova. EclecticIQ secured a €5.5m Series A and has raised €6.5m in total (approx. $7.3m). The company said it will use the new funds to expand across sectors and geographies. No other operating metrics were disclosed in the article.

Participated · Series A · Nov 2020

Tehtris develops and markets the TEHTRIS XDR Platform, an eXtended Detection and Response solution that detects and neutralizes known and unknown cyber threats in real time and without human action. The platform uses artificial intelligence, behavioral analysis, and a real-time updated threat database to orchestrate and augment traditional cybersecurity tools for augmented and hyper-automated remediation. Its sensors support operated security service provider partners that monitor millions of IP addresses and analyze tens of billions of events on systems, networks, and the cloud every week. Founded in 2010, the company has expanded operations across Europe and opened subsidiaries in Germany, Spain, Japan, and Canada. Tehtris employs more than 260 people in Europe and reports customers in more than 120 countries. The company intends to use the new funding to accelerate growth and expand operations; the raise was announced in October 2022. Tehtris develops and delivers an XDR (eXtended Detection and Response) platform that enables real-time, automated detection and neutralization of known and unknown digital threats in corporate infrastructures. Its platform is built from products, algorithms, software robots and artificial intelligence created by the company’s engineers. Tehtris and its international partners monitor millions of IP addresses in over 60 countries and analyze billions of events every week. Its customers include major players in industry, engineering and services, and it has established collaborations with Capgemini Sogeti, Orange CyberDefense and Expleo. The company was founded in 2010 by Eléna Poincet and Laurent Oudot and has more than 60 experts in France. Financially, Tehtris completed a €20M Series A round as reported.

Participated · Series A · Dec 2018

Founded in 2014 by Thierry Rouquet, Sentryo provides an ICS CyberVision platform that gives control engineers comprehensive visibility on their industrial control systems. The platform detects anomalies and accelerates response to cybersecurity incidents, helping teams manage cyber risk in M2M networks and industrial control systems. Sentryo's software is used every day by large corporations in the energy, manufacturing and transportation markets. The company raised €10M in a Series A financing in 2018. To date Sentryo has raised €13M in total.

Participated · Equity · May 2018

Kalray develops processors designed for new intelligent systems that can analyze large amounts of data on the fly, make decisions and interact in real time. Its intelligent processors are being deployed in sectors including new‑generation networks (intelligent datacenters), autonomous vehicles, healthcare, drones and robots. The company serves server manufacturers, intelligent system integrators and consumer product makers such as car manufacturers. Kalray intends to use the recently raised funds to enable commercial deployment of its existing processor and to complete development of a next‑generation processor scheduled for launch in 2019. Financially, the company raised a €10M tranche as part of a larger €23.6M financing package. Kalray was created in 2008 as a spin‑off of the CEA and is based in Grenoble, France; Eric Baissus is president and CEO. Kalray is a fabless semiconductor spin-off from the CEA (founded in 2008) led by CEO Eric Baissus. It develops the MPPA® (Massively Parallel Processor Array) manycore processors that deliver extreme computing, low power consumption and low latency. The MPPA architecture is used in critical embedded technologies, including autonomous vehicles, and for acceleration in data centers. Its technology is protected by over 20 international patents. Kalray intends to use new capital to accelerate commercial exploitation of its current solutions and to launch development of the MPPA® Coolidge, its third-generation microprocessor scheduled for release in 2018. The company has raised over $65M in capital and public funding to date and employs over 65 people across Grenoble and a North American antenna in Los Altos, CA.

Participated · Series B · Jan 2018

Pherecydes Pharma is a biotechnology company that develops precision phage therapy to treat resistant and/or complicated bacterial infections. The company has developed a portfolio of phages targeting Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa, which together account for more than two thirds of hospital-acquired resistant infections. Its precision phage therapy approach has been applied in 26 patients in the context of compassionate use under the supervision of the French National Agency for the Safety of Medicines (ANSM). Pherecydes launched clinical trials for anti‑Staphylococcus aureus phages in 2021 and planned the implementation of Early Access Programs during the second half of the year. Headquartered in Nantes and founded in 2006, the company has a team of around twenty experts from the pharmaceutical industry, biotechnology sector and academic research. Financially, Pherecydes strengthened its cash position by securing a €2 million non‑dilutive, interest‑bearing loan from Bpifrance. Pherecydes Pharma is a biotechnology company developing therapeutic bacteriophages to treat bacterial infections, particularly hospital-acquired and antibiotic-resistant cases. Its core programs include PHOSA for severe Staphylococcus aureus infections and PNEUMOPHAGE for Pseudomonas aeruginosa respiratory infections. The company plans to use new funding to produce phages for compassionate use (ATU) under GMP and to advance PHOSA and PNEUMOPHAGE into clinical phases in 2018 and 2019. It will also build a 10,000 sq ft (≈1,000 m2) pharmaceutical production unit in Nantes and launch additional research programs in 2018–2019. Financially, Pherecydes raised €8.7M in this Series B and has cumulatively raised €13.6M to date; it also receives public grants for projects such as PneumoPhage, Phosa and Phagoburn. The company is led by CEO Guy-Charles Fanneau de La Horie and COO Jérôme Gabard and employs twelve people.